{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:29:51Z","timestamp":1792877391040,"version":"4.5.0"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    We conducted a phase I-II study of the safety, tolerance, and plasma pharmacokinetics of liposomal amphotericin B (L-AMB; AmBisome) in order to determine its maximally tolerated dosage (MTD) in patients with infections due to\n                    <jats:italic>Aspergillus<\/jats:italic>\n                    spp. and other filamentous fungi. Dosage cohorts consisted of 7.5, 10.0, 12.5, and 15.0 mg\/kg of body weight\/day; a total of 44 patients were enrolled, of which 21 had a proven or probable infection (13 aspergillosis, 5 zygomycosis, 3 fusariosis). The MTD of L-AMB was at least 15 mg\/kg\/day. Infusion-related reactions of fever occurred in 8 (19%) and chills and\/or rigors occurred in 5 (12%) of 43 patients. Three patients developed a syndrome of substernal chest tightness, dyspnea, and flank pain, which was relieved by diphenhydramine. Serum creatinine increased two times above baseline in 32% of the patients, but this was not dose related. Hepatotoxicity developed in one patient. Steady-state plasma pharmacokinetics were achieved by day 7. The maximum concentration of drug in plasma (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg\/kg\/day changed to 76, 120, 116, and 105 \u03bcg\/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC\n                    <jats:sub>24<\/jats:sub>\n                    ) changed to 692, 1,062, 860, and 554 \u03bcg \u00b7 h\/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml\/h\/kg, respectively. These data indicate that L-AMB follows dose-related changes in disposition processing (e.g., clearance) at dosages of \u22657.5 mg\/kg\/day. Because several extremely ill patients had early death, success was determined for both the modified intent-to-treat and evaluable (7 days of therapy) populations. Response rates (defined as complete response and partial response) were similar for proven and probable infections. Response and stabilization, respectively, were achieved in 36 and 16% of the patients in the modified intent-to-treat population (\n                    <jats:italic>n<\/jats:italic>\n                    = 43) and in 52 and 13% of the patients in the 7-day evaluable population (\n                    <jats:italic>n<\/jats:italic>\n                    = 31). These findings indicate that L-AMB at dosages as high as 15 mg\/kg\/day follows nonlinear saturation-like kinetics, is well tolerated, and can provide effective therapy for aspergillosis and other filamentous fungal infections.\n                  <\/jats:p>","DOI":"10.1128\/aac.45.12.3487-3496.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:06:42Z","timestamp":1027750002000},"page":"3487-3496","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":344,"title":["Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with\n                    <i>Aspergillus<\/i>\n                    Species and Other Filamentous Fungi: Maximum Tolerated Dose Study"],"prefix":"10.1128","volume":"45","author":[{"given":"Thomas J.","family":"Walsh","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse L.","family":"Goodman","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Division of Infectious Diseases, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota2;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pappas","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama3;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihor","family":"Bekersky","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Fujisawa Healthcare, Inc., Deerfield, Illinois4; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald N.","family":"Buell","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Fujisawa Healthcare, Inc., Deerfield, Illinois4; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Roden","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Barrett","sequence":"additional","affiliation":[{"name":"<!--label omitted: 5-->National Heart, Lung, and Blood Institute,5 Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Anaissie","sequence":"additional","affiliation":[{"name":"<!--label omitted: 6-->Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","first-page":"S3","article-title":"AmBisome targeting to fungal infections.","volume":"14","author":"Adler-Moore J.","year":"1994","unstructured":"Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14(Suppl. 5) 1994 S3 S7","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150729"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199610000-00014"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.518"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S43"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/11.3.369"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1995.tb00020.x"},{"key":"e_1_3_1_9_2","first-page":"25","article-title":"Renal clearance of carprofen in the isolated perfused rat kidney.","volume":"9","author":"Bekersky I.","year":"1981","unstructured":"Bekersky I. Colburn W. A. Renal clearance of carprofen in the isolated perfused rat kidney. Drug Metab. Dispos. 9 1981 25 29","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_1_10_2","unstructured":"Boswell G. Rodkey W. G. Pharmacokinetics of hemoglobin infusion Advances in blood substitute research. Bolin R. B. Geyer R. P. Nemo G. J. 1983 139 147 Alan R. Liss Inc. New York N.Y"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.999.999_999_1008"},{"key":"e_1_3_1_12_2","first-page":"173","article-title":"An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome.","volume":"37","author":"Denning D. W.","year":"1998","unstructured":"Denning D. W. Marinus A. Cohen J. Spence D. Herbrecht R. Pagano L. Kibbler C. Kcrmery V. Offner F. Cordonnier C. Jehn U. Ellis M. Collette L. Sylvester R. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J. Infect. 37 1998 173 180","journal-title":"EORTC Invasive Fungal Infections Cooperative Group. J. Infect."},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097650"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.2.356"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1544"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/315643"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60129-5"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_2.S133"},{"key":"e_1_3_1_20_2","first-page":"S8","article-title":"Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.","volume":"14","author":"Heinemann V.","year":"1994","unstructured":"Heinemann V. Kahny B. Debus A. Wackholz K. Jehn U. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant. 14(Suppl.) 1994 S8 S9","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/j.1875-9114.1998.tb03934.x","article-title":"Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.","volume":"18","author":"Johnson M. D.","year":"1998","unstructured":"Johnson M. D. Drew R. H. Perfect J. R. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 18 1998 1053 1061","journal-title":"Pharmacotherapy"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/6.2.241"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.713"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00944.x"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-8-664"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.6.975"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(84)90135-4"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.83"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04825.x"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430100129015"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920601)69:11<2653::AID-CNCR2820691106>3.0.CO;2-8"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200007000-00006"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(92)90414-H"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430110089009"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.49"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.73"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.2000.279.3.H1319"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.4.509"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2431"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/516480"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Walsh T. J. Emerging fungal pathogens: evolving challenges to immunocompromised patients Emerging infections. Scheld W. M. Armstrong D. Hughes J. 1998 221 232 ASM Press Washington D.C.","DOI":"10.1128\/9781555816940.ch15"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1065"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70303-2"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2068-2076.2000"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2391"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2224"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3146"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600830716"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.2.223"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/317451"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.12.3487-3496.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.12.3487-3496.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T19:28:53Z","timestamp":1704482933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.12.3487-3496.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1128\/AAC.45.12.3487-3496.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.12.3487-3496.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]},"assertion":[{"value":"2001-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}